This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
State-of-the-Art Conference on AZT [azidothymidine; zidovudine] Therapy for Early HIV [human immunodeficiency virus] Infection, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Md, March 3 and 4:
To evaluate new information and to facilitate its transfer into clinical practice, the NIAID convened the State-of-the-Art Conference on AZT Therapy for Early HIV Infection on March 3 through 4,1990.After a day of presentations by experts and discussion by the audience, a panel composed of clinical investigators, community physicians, statisticians, and community representatives considered the available evidence and developed recommendations for clinical practice. The formulation of practice guidelines for the use of zidovudine therapy in this early infection is particularly important in view of the March 2 Food and Drug Administration approval for expanded labeling of this agent for HIV-infected individuals with CD4 lymphocyte counts of less than 500.The recommendations emanating
Recommendations for Zidovudine: Early Infection. JAMA. 1990;263(12):1606–1609. doi:10.1001/jama.1990.03440120014002
Customize your JAMA Network experience by selecting one or more topics from the list below.